| lisdexamfetamine / Generic mfg. |
| Completed | 3 | 180 | | | University of New South Wales , National Health and Medical Research Council, Curran Foundation | Addiction, Methamphetamine dependence | | | | |
NCT03924193: Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment |
|
|
| Completed | 3 | 141 | US | Lisdexamfetamine Dimesylate, Cognitive-Behavioral Therapy, Combination LDX and Cognitive-Behavioral Therapy | Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Binge-Eating Disorder, Obesity | 09/23 | 09/23 | | |
NCT03926052: Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment |
|
|
| Active, not recruiting | 3 | 80 | US | Lisdexamfetamine Dimesylate, Placebo | Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Binge-Eating Disorder, Obesity | 07/24 | 07/24 | | |
NCT04599504: Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b) |
|
|
| Enrolling by invitation | 2/3 | 60 | US | Lisdexamfetamine Dimesylate (Medication), Vyvanse, Placebo | Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Loss-of-control Eating, Obesity/Overweight | 05/27 | 05/27 | | |
